Fda Approves Gout Drug By Takeda, Teijin

Christopher Hollis

首页> 外文期刊>Washington Drug Letter >Fda Approves Gout Drug By Takeda, Teijin

【24h】

Fda Approves Gout Drug By Takeda, Teijin

机译：Fda批准帝人武田公司生产痛风药

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The FDA approved Takeda Pharmaceutical and Teijin Pharma's xanthine oxidase inhibitor Uloric for the management of chronically elevated serum uric acid levels in patients with gout.rnThe agency missed its original action date for Uloric (febuxostat) because inspections of clinical trial sites were not completed by the Jan. 18 deadline (WDL, Jan. 26).

机译：FDA批准了武田制药（Takeda Pharmaceutical）和帝人制药（Teijin Pharma）的黄嘌呤氧化酶抑制剂Uloric用于管理痛风患者的血清尿酸水平持续升高。 1月18日截止日期（WDL，1月26日）。

著录项

来源
《Washington Drug Letter》 |2009年第8期|11|共1页
作者
Christopher Hollis;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. FDA Approves Takeda's Combined-Medicine Ulcer Drug [J] . Japan Chemical Week Group Japan Chemical Week . 1997,第1934期

机译：FDA批准武田公司的联合医学溃疡药
2. Current FDA-Related Drug Information New Drugs Approved by the FDA New Dosage Forms and Indications Approved by the FDA Agents Pending FDA Approval New Drug/Biologies License Applications Filed by Manufacturer Supplemental Actions Filed by Manufacturer Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety [J] . Danial E. Baker Hospital pharmacy. . 2011,第9期

机译：当前与FDA有关的药物信息由FDA批准的新药物新剂型和适应症，由FDA代理商批准的待批FDA批准的新药/生物许可申请，由制造商提出的补充措施，由制造商提出的重要措施，或与“亲爱的健康专业人员”的信件有关安全
3. Current FDA-Related Drug Information New Drugs Approved by the FDA New Dosage Forms and Indications Approved by the FDA Agents Pending FDA Approval New Drug/Biologies License Applications Filed by Manufacturer Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety [J] . Danial E. Baker Hospital pharmacy. . 2011,第8期

机译：当前与FDA有关的药物信息由FDA批准的新药物，由FDA代理批准的新剂型和适应症，待FDA批准的新药物/生物学许可由制造商提交的重要标签变更或与安全相关的“亲爱的健康专业人员”信函
4. Using Machine Learning to Predict the Binding Dissociation of FDA Approved Drugs for Affinity- Based Drug Delivery Applications [C] . Edgardo Rivera-Delgado, Alison Xin, Horst A. von Recum Society for Biomaterials annual meeting and exposition . 2019

机译：使用机器学习预测基于亲和力的药物递送应用的FDA批准药物的结合解离
5. Molecular Determinants for Binding of the FDA-Approved Drugs in Proteins – A Data Mining and Advanced Quantum Chemical Study [D] . Alqahtani, Saad. 2017

机译：FDA批准的药物与蛋白质结合的分子决定因素–数据挖掘和先进的量子化学研究
6. Large-Scale Drug Screening in Patient-Derived IDHmut Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents [O] . Philip Dao Trong, Gerhard Jungwirth, Tao Yu, 2020

机译：患者来源的IDHmut脑胶质瘤干细胞中的大规模药物筛选在FDA批准的抗肿瘤药物中确定了几种有效药物
7. The Effectiveness of Newly FDA Approved Uloric (Febuxostat) Versus the Conventionally Used Zyloprim (Allopurinol) in Treatment of Hyperuricemia and Chronic Gout in the Adult Population [O] . Ohisa Kyle K. 2009

机译：新的FDA批准的尿酸（非布索坦）与常规使用的Zyloprim（别嘌呤醇）在成人高尿酸血症和慢性痛风中的疗效
8. Guidance for FDA Staff and Industry: Marketed Unapproved Drugs. Compliance Policy Guide. Sec. 440.100 Marketed New Drugs Without Approved NDAs or ANDAs (September 19, 2011) [R] . 2011

机译：FDa工作人员和行业指南：未经批准的未经批准的药物。合规政策指南。秒。 440.100未经批准的NDa或aNDa上市的新药（2011年9月19日）

Fda Approves Gout Drug By Takeda, Teijin

摘要

著录项

相似文献

相关主题

期刊订阅